SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-22-017488
Filing Date
2022-04-01
Accepted
2022-04-01 16:30:17
Documents
13
Period of Report
2022-03-25
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO.1 TO FORM 8-K ea157884-8ka1_allarity.htm   iXBRL 8-K/A 29325
2 RESTATEMENT OF PREVIOUSLY ISSUED UNAUDITED FINANCIAL STATEMENTS ea157884ex99-1_allarity.htm EX-99.1 63755
  Complete submission text file 0001213900-22-017488.txt   276911

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE allr-20220325.xsd EX-101.SCH 3033
4 XBRL LABEL FILE allr-20220325_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE allr-20220325_pre.xml EX-101.PRE 22595
7 EXTRACTED XBRL INSTANCE DOCUMENT ea157884-8ka1_allarity_htm.xml XML 4562
Mailing Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139
Business Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41160 | Film No.: 22798700
SIC: 2834 Pharmaceutical Preparations